ScholarLens Back to search
2022•CancerRequires access

Setting a new standard for long‐term survival in metastatic kidney cancer

Matthew Labriola, Daniel J. George

Open publisher page 1 citations

Abstract

Five‐year follow‐up data from the pivotal CheckMate‐214 trial demonstrated a persistent survival benefit with nivolumab and ipilimumab versus sunitinib in patients with metastatic renal cell carcinoma. The analysis by Motzer et al in this issue exposed the limits of pretreatment risk stratification in patients with metastatic renal cell carcinoma, particularly those who experienced a durable response to treatment, and highlighted the practice‐informing nature of conditional outcomes.

About this research paper

What this paper is about

Five‐year follow‐up data from the pivotal CheckMate‐214 trial demonstrated a persistent survival benefit with nivolumab and ipilimumab versus sunitinib in patients with metastatic renal cell carcinoma. The analysis by Motzer et al in this issue exposed the limits of pretreatment risk stratification in patients with metastatic renal cell carcinoma, particularly those who experienced a durable response to treatment, and highlighted the practice‐informing nature of conditional outcomes.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Five‐year follow‐up data from the pivotal CheckMate‐214 trial demonstrated a persistent survival benefit with nivolumab and ipilimumab versus sunitinib in patients with metastatic renal cell carcinoma. The analysis by Motzer et al in this issue exposed the limits of pretreatment risk stratification in patients with metastatic renal cell carcinoma, particularly those who experienced a durable response to treatment, and highlighted the practice‐informing nature of conditional outcomes.

Key concepts: Medicine, Term (time), Cancer, Kidney cancer, Oncology, Intensive care medicine, Internal medicine, Quantum mechanics

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Setting a new standard for long‐term survival in metastatic kidney cancer — Research Paper | ScholarLens